Teza Capital Management’s Integra LifeSciences IART Stock Holding History

Teza Capital Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,663	Closed	-$210K	–	640
2023 Q1	$210K	Buy	+3,663	New	+$206K	0.05%	455
2022 Q4	–	Sell	-8,114	Closed	-$344K	–	645
2022 Q3	$344K	Buy	8,114 +716	+10%	+$36.7K	0.07%	387
2022 Q2	$400K	Buy	+7,398	New	+$444K	0.15%	246
2020 Q1	–	Sell	-17,026	Closed	-$992K	–	304
2019 Q4	$992K	Buy	+17,026	New	+$1.01M	0.27%	97
2017 Q2	–	Sell	-9,076	Closed	-$382K	–	190
2017 Q1	$382K	Buy	+9,076	New	+$388K	0.11%	291

Other funds holding IART

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Teza Capital Management's IART Position: Q2 2023 in Review

Teza Capital Management sold out of Integra LifeSciences (IART) in Q2 2023, closing a stake of 3,663 shares — an estimated $210K sold.

Teza Capital Management first reported a position in IART in Q1 2017 and held it in 5 quarters. The position peaked at $992K in Q4 2019. 283 funds tracked by Wall St. Rank hold IART as of Q2 2023.

Teza Capital Management reported no remaining Integra LifeSciences position as of Q2 2023 after selling out during the quarter.
Teza Capital Management sold 3,663 Integra LifeSciences shares in Q2 2023, an estimated $210K.
Teza Capital Management first reported a position in Integra LifeSciences in Q1 2017 and held it in 5 quarters.
Teza Capital Management's Integra LifeSciences position peaked at $992K in Q4 2019.
283 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2023.

Based on Teza Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.